The Bespoke Gene Therapy Consortium (BGTC) is a research initiative of the US Foundation for the National Institutes of Health.[1][2] The consortium consists of the FDA, NIH, five non-profit organizations, and 10 pharmaceutical companies.[3][4][5]
References edit
- ^ "Bespoke Gene Therapy Consortium". National Institutes of Health (NIH). Foundation for the National Institutes of Health. 26 October 2021. Retrieved 7 January 2022.
- ^ "The AMP Bespoke Gene Therapy Consortium". National Center for Advancing Translational Sciences. Foundation for the National Institutes of Health. 3 January 2022. Retrieved 7 January 2022.
- ^ Begley, Anna (2021-10-28). "FDA joins Bespoke Gene Therapy Consortium (BGTC) for rare diseases". European Pharmaceutical Review. Russell Publishing Limited. European Pharmaceutical Review. Retrieved 7 January 2022.
- ^ "NIH and FDA Lead Coalition to Accelerate Gene Therapy Development for Rare Diseases". BioPharm International. MJH Life Sciences and BioPharm International. BioPharm International. 2021-10-29. Retrieved 7 January 2022.
- ^ Schneider, M.D., Christian K (2021-12-01). "FDA Keeps New Drugs Coming". PharmExec. Vol. 41, no. 12. MJH Life Sciences and Pharmaceutical Executive. Pharmaceutical Executive. Retrieved 7 January 2022.